Yuyu Pharma Inc - Asset Resilience Ratio
Yuyu Pharma Inc (000225) has an Asset Resilience Ratio of 1.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 000225 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Yuyu Pharma Inc's Asset Resilience Ratio has changed over time. See Yuyu Pharma Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Yuyu Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 000225 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.61 Billion | 1.74% |
| Total Liquid Assets | ₩3.61 Billion | 1.74% |
Asset Resilience Insights
- Limited Liquidity: Yuyu Pharma Inc maintains only 1.74% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yuyu Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Yuyu Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277 |
Drug Manufacturers - Specialty & Generic | 31.63% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 3.29% |
Annual Asset Resilience Ratio for Yuyu Pharma Inc (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Yuyu Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.74% | ₩3.61 Billion ≈ $2.45 Million |
₩207.22 Billion ≈ $140.43 Million |
+1.35pp |
| 2024-12-31 | 0.39% | ₩817.27 Million ≈ $553.85K |
₩207.69 Billion ≈ $140.75 Million |
-0.49pp |
| 2023-12-31 | 0.88% | ₩1.75 Billion ≈ $1.19 Million |
₩198.21 Billion ≈ $134.33 Million |
-1.65pp |
| 2022-12-31 | 2.53% | ₩4.94 Billion ≈ $3.35 Million |
₩195.21 Billion ≈ $132.29 Million |
+2.41pp |
| 2020-12-31 | 0.12% | ₩180.00 Million ≈ $121.98K |
₩154.90 Billion ≈ $104.97 Million |
-0.29pp |
| 2018-12-31 | 0.40% | ₩545.95 Million ≈ $369.98K |
₩135.23 Billion ≈ $91.64 Million |
-0.01pp |
| 2017-12-31 | 0.41% | ₩500.00 Million ≈ $338.84K |
₩121.49 Billion ≈ $82.33 Million |
-0.05pp |
| 2016-12-31 | 0.46% | ₩509.59 Million ≈ $345.34K |
₩111.30 Billion ≈ $75.43 Million |
-0.02pp |
| 2015-12-31 | 0.48% | ₩500.00 Million ≈ $338.84K |
₩104.33 Billion ≈ $70.70 Million |
-0.06pp |
| 2014-12-31 | 0.54% | ₩550.00 Million ≈ $372.73K |
₩101.40 Billion ≈ $68.72 Million |
-- |
About Yuyu Pharma Inc
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc.… Read more